Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) ...
Development of RNAi-Based Therapeutics using Dynamic Polyconjugates™ (DPC™) Technology," Bruce Given, M.D., Arrowhead's chief operating officer, discussed three examples of Arrowhead's broad RNAi ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has nominated ARC-HIF2 as ...
Those looking for food deliveries from the regional Arrowhead Delivery will now have to direct orders through a different app. Bite Squad, a Minneapolis-based restaurant delivery service, announced ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it has initiated dosing in a ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented an overview of its broad RNAi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback